Is BMY's Q1 2025 forecast achievable?

Bristol-Myers Squibb's (BMY) Q1 2025 forecast of $10.8 billion in revenue and an EPS of $1.55 appears to be achievable based on the following points:

1. **Analyst Confidence**: UBS maintains a neutral rating on BMY with a price target of $60, indicating potential upside from the current trading price of $59.09. This suggests that the stock may perform well, which could contribute to achieving the forecasted EPS and revenue.
2. **Product Performance**: Cobenfy, a product in BMY's portfolio, is experiencing a leveling off in total prescriptions but is expected to reach approximately 15,000 TRx in the first quarter of 2025 and about 122,000 TRx for the full year. UBS analysts estimate that Cobenfy’s sales could realistically hit between $18 million to $21 million in the first quarter of 2025, which aligns closely with the consensus estimates.
3. **Financial Resilience**: BMY has a history of maintaining dividend payments for 55 consecutive years, demonstrating resilience in navigating market challenges. The company also boasts a substantial 4.19% dividend yield, which could attract income-focused investors and contribute to the company's financial stability.
4. **Market Position**: Despite challenges with its legacy portfolio, BMY has seen higher sales of certain legacy brands, which offset increased generic volumes across other products. This suggests that the company has strategies in place to manage the impact of generics on its revenue.

In conclusion, while there are challenges, such as the impact of generics and the need to navigate a complex landscape of opportunities and challenges, the forecasted EPS and revenue for Q1 2025 seem achievable based on the company's analyst confidence, product performance, financial resilience, and market position.